Document is current
Any future updates will be listed below
-
Authors
Cao, Yuan https://orcid.org/0000-0002-3105-7654
Lizano, Paulo
Li, Meng https://orcid.org/0000-0002-8320-5241
Colic, Lejla https://orcid.org/0000-0002-8809-4034
Chand, Tara
Javaheripour, Nooshin
Sun, Huan
Deng, Gaoju
Zhou, Xiaoqin
Long, Xipeng
Gong, Qiyong https://orcid.org/0000-0002-5912-4871
Qiu, Changjian https://orcid.org/0000-0002-1906-2530
Walter, Martin https://orcid.org/0000-0001-7857-4483
Jia, Zhiyun https://orcid.org/0000-0003-1886-5654
- License Information
-
More Information
Article History
Received: 9 January 2024
Accepted: 10 April 2025
First Online: 26 May 2025
Competing interests
: M.W. is a member of the advisory boards and gave presentations for the following companies: Boehringer Ingelheim, Germany; Bayer AG, Germany; and Biologische Heilmittel Heel GmbH, Germany. M.W. has further conducted studies with institutional research support from HEEL and from Janssen Pharmaceutical Research for a clinical trial (IIT) on ketamine in patients with major depression unrelated to this investigation. M.W. has not received any financial compensation from the above-mentioned companies. The other authors declare no competing interests.
